Thermally Responsive Microcarriers for Stem Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding human mesenchymal stem cells (hMSCs) in bioreactors induce cellular senescence and reduce therapeutic potency, limiting their scalability and effectiveness in clinical applications, particularly due to issues with chemokine receptor loss, reduced migratory capacity, and increased senescence during adherent culture.
Innovation Solution
A method utilizing thermally responsive microcarriers in a bioreactor system that promotes 3D aggregation of hMSCs, allowing for non-genetic enhancement of therapeutic potency by activating anti-inflammatory cytokine secretion, reducing cell size, and enhancing resistance to ischemic stress, thereby preserving and improving the cells' innate properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hMSCs are expanded in adherent culture to increase cell population, then cell quantity is improved, but cellular senescence increases and therapeutic potency decreases
Solution Approach 1:
The patent transitions from two-dimensional adherent culture to three-dimensional suspension culture. Cells are cultured in suspension without adhering to surfaces, forming 3D aggregates that maintain stemness and therapeutic potency while enabling scalable expansion. This dimensional change eliminates the senescence-inducing effects of adherent culture.
Solution Approach 2:
The patent changes critical culture parameters: removing adherent surface contact, adjusting oxygen tension to hypoxic conditions (1-5% O2), modifying agitation patterns, and controlling cell density. These parameter changes create a culture environment that preserves cellular properties while enabling expansion.
2Quantity of substance
If hMSCs are expanded to meet clinical dose requirements, then cell quantity is improved, but migratory capacity and chemokine receptor expression decrease
Solution Approach 1:
Suspension 3D culture maintains cells in a physiological-like state without surface adhesion, preserving CXCR4 and other chemokine receptor expression. This enables cells to retain migratory capacity even at high expansion levels, solving the trade-off between dose and mobility.
Solution Approach 2:
The patent performs preliminary hypoxic pre-conditioning (1-5% O2) during expansion culture. This preliminary action primes cells to maintain their therapeutic properties and migratory capacity, preventing the loss that would occur during standard expansion.
3Productivity
If hMSCs are expanded using conventional bioreactors, then productivity is improved, but cellular senescence and loss of innate properties increase
Solution Approach 1:
The patent employs suspension 3D culture in bioreactors, moving away from conventional adherent 2D culture. This enables higher productivity through better mass transfer and cell accessibility while maintaining cellular properties through the absence of surface contact and controlled hypoxic conditions.
Solution Approach 2:
The patent optimizes bioreactor parameters including hypoxic oxygen tension (1-5% O2), agitation intensity, cell density, and media composition. These controlled parameter changes enable high expansion rates while preserving stemness and therapeutic potential.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 3D aggregation process enhances the therapeutic potential of hMSCs by maintaining their potency and viability, improving engraftment efficiency, and reducing the risk of vascular obstruction, making them more suitable for clinical translation.
Implementation Method 1
thermally responsive microcarriers (TRMs) are utilized in conjunction with a scalable bioreactor system... the cell culture temperature is reduced so that the cells detach from the TRMs
Data Source
AI summary
The subject invention concerns materials and methods for expansion of stem cells, such as mesenchymal stem cells (MSC), that improve translational success of the cells in the treatment of various conditions. The subject invention utilizes cell self-aggregation as a non-genetic means to enhance their therapeutic potency in a microcarrier bioreactor. In one embodiment of the method cells are cultured in a container or vessel in the presence of thermally responsive microcarriers (TRMs) wherein cells adhere to the surface of the TRMs. After a period of time the cell culture temperature is reduced so that the cells detach from the TRMs. The detached cells are allowed to form 3D aggregates. The 3D aggregates can be collected and treated to dissociate the cells. Dissociated cells can then be used for transplantation in methods of treatment or for in vitro characterization and study.